Dr. Jonathan Purnell
Luciole Pharmaceuticals, Inc is pleased to announce that Jonathan Q. Purnell, MD, is joining the company’s scientific advisory board.
Enhancing the repair of oxidatively damaged mitochondria may be an important therapeutic target in treating obesity and insulin resistance, either alone or in combination with existing therapeutics.”
— Dr. Jonathan Q. Purnell
NATICK, MASSACHUSETTS, UNITED STATES, September 6, 2022 /EINPresswire.com/ -- Natick, MA – September 6, 2022 - Luciole Pharmaceuticals, Inc is pleased to announce that Jonathan Q. Purnell, MD, is joining the company’s scientific advisory board. Dr. Purnell, is the Interim Director, Center for Preventive Cardiology, Knight Cardiovascular Institute (KCVI), Oregon Health & Science University (OHSU), Portland, OR, and: • Professor of Medicine, OHSU School of Medicine. • Associate Director for Obesity & Diabetes, Moore Institute for Nutrition & Wellness, OHSU. • Specializes in Endocrinology, Diabetes and Clinical Nutrition.
Dr. Purnell’s is a board-certified Endocrinologist and Obesity Medicine physician and an NIH-funded investigator who has been on faculty at OSHU since 2000. He recently became the director of the Center for Preventive Cardiology within the OHSU Knight Cardiovascular Institute. He has played a major role in establishing new resources for clinical research at OHSU, including founding the OHSU CTRC Body Energy and Composition Core and serving as Associate Director of the OHSU Clinical and Translational Research Center and the Director of the Clinical and Translational Research Center Bionutrition unit. In this capacity he provided expertise to clinical investigators on the core resources to measure energy expenditure, body composition, and body fat distribution. He also has...